The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?

about

The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?

Item

http://www.wikidata.org/entity/Q38683638

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The use of systemic therapies ...... add on cytotoxic combinations?

@en

type

Item

label

The use of systemic therapies ...... add on cytotoxic combinations?

@en

prefLabel

The use of systemic therapies ...... add on cytotoxic combinations?

@en

P1476

The use of systemic therapies ...... add on cytotoxic combinations?

@en

P2093

Anthony Gonçalves

http://www.w3.org/2001/XMLSchema#string

Audrey Monneur

http://www.w3.org/2001/XMLSchema#string

François Bertucci

http://www.w3.org/2001/XMLSchema#string

P2860

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Molecular portraits of human breast tumours

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

ALK gene amplified in most inflammatory breast cancers

P304

593-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1330655

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrice Viens

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28506194

http://www.w3.org/2001/XMLSchema#string